Abstract
Histone deacetylases (HDACs) regulate gene expression by modulating chromatin architecture via histone hypoacetylation. They play a key role in regulating cellular processes including cell cycle arrest and apoptosis. Hyperactivity of HDACs plays a key role in tumour onset and progression making these enzymes as striking targets for anticancer drugs and therapy. Certain cancers are associated with upregulation of specific class II HDAC isoform rather than multiple ones. Therapeutic intervention using small-molecules namely histone deacetylase inhibitors (HDACi), often targets many isoforms unselectively (pan-HDACi) due to structural identity culminating in debilitating off-target effects and reduced in vivo potency. This emphasizes the escalating need for developing isoform-selective inhibitors against the defined class of HDACs. Despite the safe and elevated therapeutic benefit, the design of such inhibitors has been challenging. The present article provides intricate details about the role of class II HDAC isoforms in fuelling distinct cancers and the current challenges with the use of pan-HDAC inhibitors in anticancer therapy. The article also highlights the diverse synthetic and in silico approaches taken by scientific community towards the designing of isoform-selective inhibitors against class II HDAC isoforms. The strategies discussed in this review will provide further impetus to the ongoing research regarding the designing of isoform-selective inhibitors for safe and effective anticancer therapy which is today’s need.
Keywords: Histone deacetylases, Histone deacetylase inhibitors, Pan-inhibitors, Isoform-selective inhibitors, Cancer.
Current Topics in Medicinal Chemistry
Title:Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Volume: 16 Issue: 22
Author(s): Shabir Ahmad Ganai
Affiliation:
Keywords: Histone deacetylases, Histone deacetylase inhibitors, Pan-inhibitors, Isoform-selective inhibitors, Cancer.
Abstract: Histone deacetylases (HDACs) regulate gene expression by modulating chromatin architecture via histone hypoacetylation. They play a key role in regulating cellular processes including cell cycle arrest and apoptosis. Hyperactivity of HDACs plays a key role in tumour onset and progression making these enzymes as striking targets for anticancer drugs and therapy. Certain cancers are associated with upregulation of specific class II HDAC isoform rather than multiple ones. Therapeutic intervention using small-molecules namely histone deacetylase inhibitors (HDACi), often targets many isoforms unselectively (pan-HDACi) due to structural identity culminating in debilitating off-target effects and reduced in vivo potency. This emphasizes the escalating need for developing isoform-selective inhibitors against the defined class of HDACs. Despite the safe and elevated therapeutic benefit, the design of such inhibitors has been challenging. The present article provides intricate details about the role of class II HDAC isoforms in fuelling distinct cancers and the current challenges with the use of pan-HDAC inhibitors in anticancer therapy. The article also highlights the diverse synthetic and in silico approaches taken by scientific community towards the designing of isoform-selective inhibitors against class II HDAC isoforms. The strategies discussed in this review will provide further impetus to the ongoing research regarding the designing of isoform-selective inhibitors for safe and effective anticancer therapy which is today’s need.
Export Options
About this article
Cite this article as:
Ganai Ahmad Shabir, Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy, Current Topics in Medicinal Chemistry 2016; 16 (22) . https://dx.doi.org/10.2174/1568026616666160212122609
DOI https://dx.doi.org/10.2174/1568026616666160212122609 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hepatitis B Virus X Protein Modulates Chemokine CCL15 Upregulation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors
Current Pharmaceutical Design Bringing Light into the Diagnosis of Skin Disorders - Short Review on Laser Induced Fluorescence Spectroscopy and Optical Coherence Tomography in Dermatology
Current Medical Imaging Biologically Active Phytochemicals: A Brief Appraisal
Current Traditional Medicine Exploring Pharmacological Significance of Chalcone Scaffold: A Review
Current Medicinal Chemistry Applications and Toxicity of Silver Nanoparticles: A Recent Review
Current Topics in Medicinal Chemistry Reducing the Burden of Cervical Cancer in the Developing World
Current Women`s Health Reviews Targeting the HIF-1α/Cav-1 Pathway with a Chicory Extract/Daidzein Combination Plays a Potential Role in Retarding Hepatocellular Carcinoma
Current Cancer Drug Targets Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
Current Pharmaceutical Design Glucose Transporters in Sex Steroid Hormone Related Cancer
Current Vascular Pharmacology Small Molecules Activating TrkB Receptor for Treating a Variety of CNS Disorders
CNS & Neurological Disorders - Drug Targets Novel Concepts in the Development of Platinum Antitumour Drugs: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Calcium Carbonate Microparticles as Carriers of <sup>224</sup>Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer
Current Radiopharmaceuticals Treatment of Pancreatic Cancer with Pharmacological Ascorbate
Current Pharmaceutical Biotechnology Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
Current Pharmaceutical Design Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes
Current Drug Therapy A Review on the Synthesis and Anti-cancer Activity of 2-substituted Quinolines
Anti-Cancer Agents in Medicinal Chemistry Immune Responses to Adeno-Associated Virus Vectors
Current Gene Therapy